Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired spermatogenesis, testosterone defi ciency, and physical sexual dysfunction in male pubertal, adolescent, and young adult cancer survivors. Guidelines for surveillance and management of potential adverse eff ects could improve cancer survivors' health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about optimum screening practices. This clinical practice g uideline recommended by the International Late Eff ects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an international multidisciplinary panel including 25 experts in relevant medical specialties, using a consistent and transparent process. Recommendations were graded according to the strength of underlying evidence and potential benefi t gained by early detection and appropriate management. The aim of the recommendations is to enhance evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, highlighting the need for further targeted research.
Introduction
Advances in the treatment of childhood, adolescent, and young adult (CAYA) cancer have led to 5-year survival exceeding 80%. 1, 2 Unfortunately, many CAYA cancer survivors experience long-term morb idity and mortality resulting from cancer, treatment, or both. 3, 4 The risk of treatment-induced gonadotoxicity often causes emotional distress for male survivors [5] [6] [7] [8] [9] [10] and impaired spermatogenesis results in reduced or lost fertility. 5, 7 Testosterone defi ciency causes delayed or arrested puberty in adolescents, and many adverse somatic and psychological consequences in adults. 6, 8, 11, 12 Sexual dysfunction can have both phys ical and psychosexual consequences. 10, 13 Male survivors at risk of cancer and treatment-related gonadotoxic eff ects and their health-care providers could benefi t from clinical practice guidelines to facilitate timely remedial or health-preserving interventions. [14] [15] [16] [17] P ublished clinical practice guidelines developed by North American and European groups for long-term follow-up of CAYA cancer survivors [18] [19] [20] [21] vary in defi nitions of at-risk populations and recommendations for treatment modalities and frequency of surveillance. Because diff erences in published guidelines might hinder guideline implementation and provision of consistent clinically eff ective care, the International Late Eff ects of Childhood Cancer Guideline Harmonization Group (IGHG) was developed to critically examine the evidence and harmonise existing long-term follow-up guidelines. 22 The European Union-funded PanCareSurFup (PCSF) Consortium collaborated with IGHG to identify treatments associated with increased risk of impaired spermatogenesis, testosterone defi ciency, and physical sexual dysfunction in male CAYA cancer survivors, and evaluate surveillance strategies. This Review summarises the evidence and recommendations. Treatment of impaired sperma togenesis, testosterone defi ciency and physical sexual dysfunction by relevant specialist clinicians was not included in this Review. Review guideline methodology (three members). The group worked together via web conferences, face-to-face meetings, and email correspondence.
The experts looked for areas of concordance and discordance across the COG, DCOG, SIGN, and CCLG guidelines. They devised clinical questions to address areas of discordance for surveillance of impaired spermatogenesis, testosterone defi ciency, and physical limitations that lead to sexual dysfunction (subsequently described as physical sexual dysfunction) covering the following key issues: who needs surveillance; which surveillance modality should be used; how often and for how long surveillance should be performed; and when survivors should be referred (appendix pp 1-3).
Methods
We did systematic searches in the medical literature for studies of CAYA survivors (see appendix, pp 4-10, for more details).
Search strategy and selection criteria
Systematic literature searches were performed between January, 1993 and October, 2014 (appendix, pp 4-10). We searched MEDLINE (through PubMed) using the search terms "childhood cancer", "male", "alkylating agents", "platinum agents", "radiotherapy", "orchidectomy", "impaired spermatogenesis", "testosterone defi ciency", "sexual dysfunction", "FSH", "inhibin B", "LH", "testosterone" (detailed search strategies are provided in the appendix, pp 4-10). We critiqued references supporting the existing recommendations and contacted experts in the specialty to determine if any additional evidence was available. Only reports published in English were reviewed. The inclusion criteria were based on study population, outcomes, type, and date of study. Eligible study populations were male human childhood, adolescent, and young adult cancer survivors, in which 75% or more had been diagnosed with cancer before the age of 25 years and 50% or more had been followed up for 2 years or more after cancer diagnosis. Eligible study outcomes were impaired spermatogenesis (azoospermia, oligozospermia) or testosterone defi ciency. All study designs were eligible (including diagnostic studies to address which surveillance modality should be used) if the sample size included 20 patients or more and if the study controlled for important confounding factors, such as treatment or age (eg, cohort study using a multivariable or multiple regression analysis or case control study that used measures to control for important factors). Studies that used only a univariable analysis were excluded. Studies published from 1993 onwards were eligible.
Studies meeting the inclusion criteria were selected and evidence summaries were generated to answer the clinical questions. The fi nal selection of studies was based on relevance to the broad scope of this guideline. In the case of concordance, the evidence cited by the guidelines was evaluated.
Papers were selected for evidence summaries if they reported a primary outcome. Conclusions based on gonado trophins alone were not used to inform surveillance recommendations for impaired spermato genesis or testosterone defi ciency because they were not defi ned as primary outcomes and patients treated with cranial radiotherapy might develop hypogonadotropic hypogonadism, and hence blunted gonadotrophin responses.
Studies of surveillance modalities for impaired spermatogenesis calculated the area under the curve (AUC) of the receiver operating characteristics (ROC) curves to evaluate accuracy of a diagnostic investigation. We used Tape's criteria, 24 based on the numerical value of the AUC of the ROC curve, to analyse the diagnostic value of investigations.
In cases whereby no or only low-quality evidence was identifi ed for the gonadotoxic eff ect (or absence) of a treatment, relevant information was extrapolated from studies that did not meet the systematic search's eligibility criteria, including studies published before 1993. Conclusions from this supplemental search were agreed upon and described as refl ecting expert opinion. They were categorised as probably demonstrating an eff ect or no eff ect of the treatment, or as suggesting that the risk was unclear. For a full fl owcharton the studies selected see fi gure 1.
Defi nitions used
Given the heterogeneity in defi nitions of relevant therapeutic exposures, surveillance strategies and clinical outcomes, we developed standardised defi nitions for our literature review and fi nal recommendations.
CAYA cancer survivors were defi ned as individuals diagnosed with cancer up to 25 years of age and at least 2 years after completion of treatment, regardless of current age.
Chemotherapy drugs included in the literature searches were alkylating and similar DNA interstrand crosslinking agents, including bifunctional classical alkylators (busulfan, chlorambucil, cyclophosphamide, ifosfamide, chlormethine, melphalan, thiotepa), platinum agents (carboplatin, cisplatin), and monofunctional nitrosoureas (carmustine, lomustine), and triazenes (dacarbazine, procarbazine, temozolomide). These drugs are subsequently referred to collectively as alkylating agents. Cytarabine was also included in view of reports of potential gonadotoxicity. 25, 26 Radiotherapy potentially exposing the testes or pelvis included the following treatment volumes: testes, fl ank or hemi-abdomen if the radiotherapy fi eld extended below the iliac crest, whole abdomen, inverted Y (paraaortic, iliac, inguinal, and upper femoral lymph nodes, often with spleen or splenic pedicle), pelvis, prostate, bladder, iliac, inguinal, femoral, thigh, total lymphoid irradiation, total nodal irradiation, and total body irradiation (TBI). Although radiotherapy (eg, cranial) that potentially exposes the hypothalamic-pituitary region might cause central hypogonadism and was included in our search strategy, we did not develop surveillance recommendations because this will be evaluated in a future IGHG/PCSF pituitary dysfunction guideline.
Primary and other outcomes were defi ned. For primary outcomes, impaired spermatogenesis was defi ned as azoospermia or oligozoospermia demonstrated by semen analysis, testosterone defi ciency as decreased serum testosterone concentrations, and physical sexual dys function as erectile or ejaculatory dysfunction, or impotence. Reference ranges were the same as those used in the selected articles. Other outcomes evaluated included elevated serum follicle-stimulating hormone (FSH), or reduced serum inhibin B concentration (for impaired spermatogenesis), and elevated serum luteinising hormone (LH) concentration (for testosterone defi ciency). Delayed puberty was defi ned as failure to develop signs of puberty by 14 years of age. Failure of pubertal progression was defi ned as no change in pubertal stage for at least 6 months at the age at which progression would be expected.
Final recommendations
Final recommendations were based on scientifi c knowledge in the evidence summaries, combined with other considerations including clinical judgements, decisions about thresholds, costs, potential harms from excessive screening, and the need to maintain fl exibility of application across diff erent health-care systems. The quality of the evidence and the strength of the recommendations were graded according to published evidence-based methods (appendix pp 11-12). 22, 27, 28 The harmonised male gonadotoxicity surveillance recommendations were critically appraised by two independent external experts in the fi eld and fi ve survivor representatives. Tables 1-3 show the concordances and discordances between existing surveillance recommendations for impaired spermatogenesis, testosterone defi ciency, and physical sexual dysfunction.
Findings
Many areas of discordance were identifi ed that required more detailed investigation of the evidence. The appendix presents the clinical questions (pp 1-3), evidence summaries (pp , and conclusions of evidence tables (pp [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] for the evidence summaries, and summarises evidence from and provides references for studies identifi ed by the supplemental search (pp [49] [50] [51] [52] [53] .
Of 3202 studies of impaired spermatogenesis, testosterone defi ciency, and physical sexual dysfunction identifi ed, seven met all inclusion criteria to address who needs surveillance and at what frequency (fi gure 1A). Of 1170 studies of impaired spermatogenesis and testosterone defi ciency identifi ed, six met all inclusion criteria to address which surveillance modality should be used (fi gure 1B).
Impaired spermatogenesis Who needs surveillance?
The existing surveillance recommendations were discordant about which chemotherapy, radiotherapy, and surgery exposures place CAYA cancer survivors at risk of impaired spermatogenesis.
We found that cyclophosphamide and the combination of chlormethine and procarbazine have been associated with increased risk of impaired Review spermatogenesis (level C evidence). 29, 30 Higher doses had greater risks than did lower doses (levels B and C). [29] [30] [31] However, one study 30 suggested that higher dacarbazine doses were no more toxic to spermatogenesis than lower doses (level C) but no studies compared patients who received or did not receive dacarbazine. No studies evaluated impaired spermatogenesis risk after treatment with other alkylating agents, platinum agents, or cytarabine.
Only weak evidence from the systematic search showed that TBI was associated with increased impaired spermatogenesis risk (level C). 32 No studies compared MOPP=mustargen (chlormethine, nitrogen mustard), oncovin (vincristine), procarbazine, prednisone. HSCT=haematopoietic stem cell transplant. LH=luteinising hormone. *Busulfan, chlorambucil, cyclophosphamide, ifosfamide, chlormethine, melphalan, thiotepa, carmustine, lomustine. †Radiotherapy potentially exposing the testes: whole abdomen, pelvic, testicular, prostate, fl ank or hemi-abdomen (if extended below iliac crest), inverted Y (para-aortic, iliac, inguinal, and upper femoral lymph nodes, often with spleen or splenic pedicle), bladder, iliac, inguinal, femoral, total lymphoid irradiation, total body irradiation. ‡Not for screening purposes; refer to endocrinology at 11 years of age for initiation of hormonal replacement therapy to induce puberty. In the supplemental search, we identifi ed several studies with important limitations (in terms of failing to meet all the inclusion criteria), but still refl ecting expert opinion (appendix pp 49-53 for references). It was agreed that an increased risk of impaired spermatogenesis probably exists after treatment with busulfan and cyclophosphamide, or fl udarabine and melphalan, haematopoietic stem-cell transplant (HSCT) conditioning, ifosfamide doses of more than 60 g/m², radiotherapy potentially exposing testes to more than 2-3 Gy, and TBI. Transient impairment of spermato genesis is expected and permanent impairment has been reported after radiotherapy treatment potentially exposing testes to less than 2-3 Gy, but there is probably not a substantially increased risk after these small doses, or after unilateral orchiectomy. The risks of impaired spermatogenesis after treatment with cisplatin are unclear.
The panel recommended that survivors treated with one or more potentially gonadotoxic agents should be advised of, and counselled about, the risk of impaired spermatogenesis and its implications for future fertility (strong recommendations; level C evidence, supplemental search and expert opinion). Agents with potential to impair spermatogenesis include cyclophosphamide, chlormethine, and procarbazine (level C), ifosfamide, busulfan/ cyclophosphamide or fl udarabine/melphalan, HSCT conditioning, and radiotherapy potentially exposing the testes (supplemental search and expert opinion). Because of interpatient variability and insuffi cient evidence, it is not possible to make recommendations regarding riskstratifi ed surveillance strategies based on either dose thresholds or age at treatment.
Which surveillance modality should be used?
The existing surveillance recommendations were concordant in stating that Tanner stage 33, 34 and testicular volume, serum FSH, and semen analysis should be evaluated, but discordant for serum inhibin B measurement.
We found three studies Review concentrations in detecting azoospermia, one study for excluding azoospermia, 37 and one for detecting oligospermia (defi ned as <20 × 10⁶/mL). 38 One study 32 evaluated the diagnostic value of serum FSH for excluding azoospermia. Two studies 35, 36 also investigated the diagnostic value of the combination of serum inhibin B and FSH for detecting azoospermia and one for detecting oligospermia. 38 The results are summarised in the appendix (pp [43] [44] [45] . AUCs of the ROC curve are approximately 0·7-0·8, suggesting that measurements of FSH, inhibin B, and inhibin B to FSH ratio all have fair diagnostic value for detecting azoospermia (level B evidence for FSH and inhibin B, level C for inhibin B to FSH ratio).
The panel recommended that for survivors who desire assessment about possible future fertility after treatment with potentially gonadotoxic therapy, semen analysis should be the gold standard as the primary surveillance modality for evaluating spermatogenesis (strong recommendation; expert opinion).
Clinical measurement of testicular volume, serum FSH, and inhibin B might be reasonable tests for identifying impaired spermatogenesis in survivors treated with potentially gonadotoxic therapy in whom semen analysis has been declined or is not possible, and who desire assessment about their possible future fertility (weak recommendation; level B evidence). However, it is important to be aware of the diagnostic limitations of these tests (appendix pp [25] [26] [27] [28] [29] [39] [40] [41] .
At what frequency and for how long should surveillance be performed?
The existing surveillance recommendations are discordant regarding the frequency and duration of surveillance for impaired spermatogenesis, except for partial concordance regarding semen analysis.
No studies were identifi ed that provided information about the probability, rate, or timing of changes (improvement or deterioration) in spermatogenesis parameters in male survivors treated with potentially gonadotoxic therapy.
The panel recommended surveillance for impaired spermatogenesis be performed only at the request of the survivor after informed discussion or when paternity is desired in the foreseeable future (strong recommendation; expert opinion).
When should survivors be referred?
The existing surveillance recommendations are concordant regarding the timing of referral for impaired spermatogenesis but discordant regarding situations in which assisted reproductive technologies should be considered. A literature search was not performed because we considered that expert opinion allowed formulation of a pragmatic referral recommendation.
It is recommended that referral to a male reproductive health specialist should be off ered to survivors with severe oligozoospermia (sperm counts ≤5 × 10⁶/mL), to individuals seeking paternity after potentially gonadotoxic therapy, or to survivors whose attempts to conceive have been unsuccessful for 6 months or more, 39 regardless of sperm count, for detailed specialist counselling or consideration of sperm cryopreservation if not already performed (strong recommendation; expert opinion).
Testosterone defi ciency
The clinical presentation of testosterone defi ciency varies with the age at onset. In prepubertal and peripubertal males, testosterone defi ciency causes delayed or arrested puberty, respectively. In postpubertal males, testosterone defi ciency leads to reduced sexual function and numerous systemic consequences including fatigue and increased cardiovascular risk. 40 
Who needs surveillance?
The existing surveillance recommendations were discordant with respect to which chemotherapy, radiotherapy, and surgery exposures place CAYA cancer survivors at risk of testosterone defi ciency.
In the systematic search, two studies 41, 42 revealed no increased risk of testosterone defi ciency after cyclophosphamide treatment (level C evidence); one study 42 also found no increased risk after procarbazine or platinum agents (level C). Another study 43 found no increased risk after higher chlorambucil (672 mg/m²) and procarbazine (11 200 mg/m²) doses, compared with lower doses (504 and 8400 mg/m²; level C). No studies compared diff erent cyclophosphamide or platinum agent doses. No studies investigated risk after other alkylating agents or cytarabine.
One study 42 found no increased testosterone defi ciency risk after radiotherapy potentially exposing the testes (pelvic or abdominal, or TBI, doses not specifi ed; level C). No studies were identifi ed that addressed risk after diff erent radiotherapy doses, or after unilateral orchiectomy.
One multivariable study 42 showed that age at treatment had no eff ect on testosterone defi ciency risk, although only a minority of survivors had received radiotherapy potentially exposing the testes (level C).
In the supplemental search, several studies with important limitations (in terms of failing to meet all inclusion criteria), but refl ecting expert opinion, were identifi ed (appendix pp 49-53 for references). An increased risk of testosterone defi ciency is probable after radiotherapy treatment that potentially exposes the testes to more than 12 Gy of radiation or with TBI (7·5-15 Gy). An increased risk of testosterone defi ciency is unlikely after radiotherapy potentially exposing testes to less than 12 Gy. According to this evidence and comparability with contemporary TBI schedules, a consensus was reached within the group that a testicular radiotherapy dose threshold of 12 Gy or more, or TBI, is probably associated with increased risk.
An increased risk after treatment with cyclophosphamide, busulfan and cyclophosphamide, or fl udarabine Review and melphalan, HSCT conditioning, procarbazine and chlormethine, ifosfamide, and cisplatin is probable.
The panel recommended that survivors treated with a potentially gonadotoxic agent should be advised of, and counselled about, the risk of testosterone defi ciency and its implications for future health and fertility (strong recommendations; supplemental search or expert opinion). Treatments with the potential to cause testosterone defi ciency include radiotherapy potentially exposing the testes to 12 Gy or more, and TBI (supplemental search or expert opinion). No recommendation can be made regarding risk-stratifi ed surveillance strategies based on age at treatment.
Which surveillance modality should be used, at what frequency, and for how long?
The existing surveillance recommendations for testosterone defi ciency are concordant in stating that Tanner stage and testicular volume should be evaluated, and serum testosterone and LH concentration measured. They are partially concordant for measuring height and weight, recommended for all survivors by the CCLG, DCOG, and SIGN guidelines but only for detecting precocious puberty by the COG guidelines. They are discordant regarding the frequency and duration of surveillance.
No studies were identifi ed in the systematic or supplemental searches regarding the diagnostic value of single, compared with serial, serum LH or testosterone measurements to detect testosterone defi ciency in postpubertal male survivors treated with potentially gonadotoxic therapy. Similarly, no studies were identifi ed that provided information about the probability, rate, or timing of changes (improvement or deterioration) in testosterone defi ciency.
The clinical presentation of testosterone defi ciency in CAYA cancer survivors depends on age and can include delayed or arrested puberty, or a variety of clinical manifestations in postpubertal males. The following recommendations describe surveillance for each scenario.
Monitoring of growth (height) and pubertal development and progression (Tanner stage, testicular volume) is recommended for prepubertal and peripubertal cancer survivors treated with radiotherapy potentially exposing testes to 12 Gy or more, or with TBI (strong recommendation; expert opinion). This monitoring should commence at no later than 12 years of age and should be performed at least annually, with increasing frequency as clinically indicated depending on growth and pubertal progress. In survivors who received cranial radiation, it should be noted that the pubertal increase in growth velocity may be impaired if growth hormone defi ciency is also present.
Measurement of total testosterone concentration in an early morning blood sample at clinically appropriate intervals is reasonable in postpubertal survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more, or with TBI (moderate recommendation; expert opinion). In the presence of clinical signs of hypogonadism, previous low-normal or borderline testosterone concentrations, or in cases whereby it is not possible to obtain an early morning blood sample, measurement of LH concentration is reasonable in addition to testosterone (moderate recommendation; expert opinion).
When should survivors be referred?
The existing surveillance recommendations are concordant regarding the timing of referral for testosterone defi ciency. A literature search was not performed because we considered that expert opinion allowed formulation of a pragmatic referral recommendation.
Referral to a paediatric endocrinologist is recommended for any male survivor who has no signs of puberty by 14 years of age, or who shows failure of pubertal progression (strong recommendation; expert opinion).
Referral to a specialist in male reproductive health, andrology, endocrinology, or urology (depending on local referral pathways) is recommended for postpubertal male survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more, or with TBI, and in whom laboratory results (reduced serum testosterone or increased serum LH concentration) suggest testosterone defi ciency (strong recommendation; expert opinion).
Physical sexual dysfunction Who needs surveillance?
The existing surveillance recommendations were discordant with respect to which chemotherapy, radiotherapy, and surgery exposures place CAYA cancer survivors at risk of physical sexual dysfunction.
The systematic search identifi ed no studies reporting on risks for treatment-related physical sexual dysfunction after childhood cancer. The supplemental search identifi ed several studies with important limitations (in terms of failing to meet all inclusion criteria), but refl ecting expert opinion, were identifi ed (appendix pp 49-53 for references). These studies suggested that hypogonadism (ie, decreased serum testosterone) is probably associated with an increased risk of sexual dysfunction. Surgery to the spinal cord, sympathetic nerves or pelvis, or radiotherapy potentially exposing the testes or pelvis, are probably each associated with an increased risk of sexual dysfunction.
The panel recommended that survivors treated with one or more treatment modalities with the potential to cause physical sexual dysfunction should be advised of, and counselled about, the risk of such dysfunction and its implications for future health and fertility (strong recommendation; supplemental search and expert opinion). Treatments with potential to cause physical sexual dysfunction include surgery to the spinal cord, sympathetic nerves or pelvis, radiotherapy potentially www.thelancet.com/oncology Vol 18 February 2017 e83 Review exposing the testes or pelvis, or any treatment that causes hypogonadism (supplemental search and expert opinion).
Which surveillance modality should be used?
The existing surveillance recommendations are discordant regarding surveillance modalities for physical sexual dysfunction. We did not perform a search as clinical history is the only available surveillance tool.
It is recommended that health-care providers should take a relevant sexual history in postpubertal survivors treated with surgery to the spinal cord, sympathetic nerves or pelvis, or radiotherapy potentially exposing the testes or pelvis, or individuals who have been diagnosed with hypogonadism (strong recommendation; expert opinion).
It is not possible to formulate any recommendations about the frequency or duration of surveillance for physical sexual dysfunction in survivors.
When should survivors be referred?
The existing surveillance recommendations are discordant for the timing of referral for physical sexual dysfunction . A literature search was not performed because we considered that expert opinion allowed formulation of a pragmatic referral recommendation.
The panel recommended referral to a specialist in male reproductive health, andrology, endocrinology, or urology (according to local referral pathways) for survivors treated with surgery to the spinal cord, sympathetic nerves or pelvis, or radiotherapy potentially exposing the testes or pelvis, or those who have hypogonadism, and have symptoms suggestive of physical sexual dysfunction (strong recommendation; expert opinion).
Discussion
We present the international harmonised surveillance recommendations for gonadal dysfunction in male CAYA cancer survivors. Table 4 summarises the conclusions of the evidence from both the systematic and supplemental searches. Figure 2 presents the fi nal recommendations and the panel presents the gaps in knowledge and future directions for research. The recommendations were derived from critical analysis of the published literature, using strict standards to grade supporting evidence, supplemented by expert consensus in areas in which little or no evidence was available.
Few published studies performing semen analysis or measuring serum testosterone in male CAYA cancer survivors were identifi ed by our systematic search. Additionally, many studies did not mention whether testosterone was measured in early morning samples, limiting their utility. The search provided clear evidence for the gonadotoxicity of some modalities used in the treatment of CAYA cancer, but did not provide evidence for several other modalities that are widely believed to cause impaired spermatogenesis or testosterone defi ciency (eg, radiotherapy exposing the testes). Evidence for associations between certain treatment modalities and impaired spermatogenesis or testosterone defi ciency derives from studies that did not evaluate the primary outcomes (semen analysis, serum testosterone), were performed in other populations (eg, adults >25 years), included less than 20 patients, did not use statistical analyses that accounted for confounding factors, or predated 1993, and hence did not meet the systematic search's inclusion criteria. Although many older publications (pre-1993) provide important insights, most did not evaluate the primary outcomes chosen or account for confounding factors. In view of the importance of the additional evidence that is available from the literature that did not meet the inclusion criteria, we performed a further supplemental search to evaluate this evidence in more detail. For some questions, the supplemental search provided data concerning risks and dose thresholds for toxicity of chemotherapeutic agents and testicular radiotherapy, optimising identifi cation of treatments with or without evidence of probable gonadotoxicity, and assisting formulation of our recommendations. To ensure transparency of the guide line development process, the results of the systematic and supplemental searches are presented separately, and their contributions to the recommendations stated clearly.
The systematic search provided evidence for adverse eff ects of cyclophosphamide, chlormethine and procarbazine on spermatogenesis, whereas the supplemental search demonstrated evidence for the probable toxicity of busulfan and cyclophosphamide, or fl udarabine and melphalan combinations, and ifosfamide. Longstanding clinical experience has shown that testicular radiotherapy impairs spermatogenesis. 6, 44 The supplemental search provided evidence to support this observation from several sources including univariable studies, studies employing outcomes other than semen analysis (eg, FSH), or performed in adult cancer survivors. Although one study 32 found no increased risk of impaired spermatogenesis after TBI on multivariable regression analysis, the comparator (non-TBI) group included individuals given other potentially gonadotoxic treatments including cyclophosphamide and busulfan. Therefore, for TBI, greater emphasis was placed on the results of the supplemental search. We identifi ed no evidence that age at exposure infl uences susceptibility to impaired spermatogenesis, thus it appears reasonable to extrapolate evidence from adult studies.
Risk factor evaluation for impaired spermatogenesis, particularly exposure to specifi c treatment agents, is problematic. Potentially gonadotoxic drugs are frequently used in combination chemotherapy regimens and can also be used with radiotherapy potentially exposing the testes, sometimes with uncertain dosimetry. Many studies are small, retrospective, use varied doses, and do not allow for confounding factors. Alkylating agents used in combination are considered to have an additive adverse eff ect on spermatogenesis. 6 Review may be another important variable given evidence of variable fertility or even late recovery of spermatogenesis during prolonged follow-up in some survivors. [45] [46] [47] [48] [49] Even when these factors are controlled in studies whereby patients have received the same treatment exposures and have similar follow-up durations, interindividual diff erences in vulnerability persist, possibly refl ecting genetic infl uences. 31, 50 Several studies have suggested an association between alkylating agent dose and the probability of impaired spermatogenesis. 31 Additionally, a 2016 study 51 found an association between higher cyclophosphamide, ifosfamide, procarbazine, and cisplatin doses and reduced probability of siring a pregnancy. However, although uncommon, azoospemia and oligozoospermia can occur after cyclophosphamide equivalent doses of less than 4000 mg/m², 31 and it has not been possible to establish a completely safe lower dose threshold. 5, 50 Although the supplemental study suggested that testicular radiotherapy doses of more than 2-3 Gy are probably associated with a substantially increased risk of chronic spermatogeniesis impairment, whereas lower doses are unlikely to be associated with an increased risk, it is well known that even very small doses invariably cause acute impairment and that recovery does not always occur. 44, 52 Given this variability and the diffi culty of excluding toxicity even with small doses, we concluded that any dose of potentially gonadotoxic alkylating agents or testicular radiotherapy should be regarded as possibly increasing the risk of impaired spermatogenesis.
Although the systematic search did not reveal evidence that alkylating agents, or radiotherapy potentially exposing the testes, are associated with an increased risk of testosterone defi ciency, the supplemental search identifi ed several studies suggesting that testicular radiotherapy probably leads to increased risk. This eff ect was observed in all studies describing testicular radiotherapy doses of 21-24 Gy or more and most studies evaluating doses of For the key question 'who needs surveillance' we performed a supplemental literature search. We only performed and reported the supplemental search when there was no evidence available in the systematic search or if there was evidence not supporting an eff ect. If there were no studies available we reported this as 'no studies'. Level A=high level of evidence. Level B=moderate/low level of evidence. Level C=very low level of evidence. CAYA=childhood, adolescent, and young adult. TBI=total body irradiation. HSCT=haematopoietic stem cell transplant. FSH=follicle-stimulating hormone. *Refers to risk of permanently impaired spermatogenesis. †Given as part of multiagent treatment including procarbazine. ‡Given as part of multi-agent treatment including chlormethine. §Busulfan, chlorambucil, ifosfamide, melphalan, thiotepa, carmustine, lomustine. ¶Carboplatin, cisplatin. ||Expert opinion based on studies of the supplemental literature search that did not fulfi l the inclusion criteria or were of very low quality (appendix pp 49-53). **Given as part of multi-agent treatment including chlorambucil. † †Busulfan, chlormethine, ifosfamide, melphalan, thiotepa, carmustine, lomustine. 
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Impaired spermatogenesis
General recommendation Survivors treated with one or more potentially gonadotoxic agents, and their health-care providers, should be aware of the risk of impaired spermatogenesis and its implications for future fertility (level C evidence and supplemental literature search and expert opinion)
Who needs surveillance?
General recommendation
Counselling regarding the risk of impaired spermatogenesis and its implications for future fertility is recommended for survivors treated with:
• Cyclophosphamide, chlormethine, procarbazine (level C evidence), busulfan and cyclophosphamide or fludarabine and melphalan for haematopoietic stem-cell transplant, ifosfamide (supplemental literature search and expert opinion) • Radiotherapy potentially exposing testes (supplemental literature search and expert opinion) Which surveillance modality should be used?
General recommendation
Who needs surveillance?
Which surveillance modality should be used?
In survivors who desire assessment about possible future fertility after treatment with potentially gonadotoxic chemotherapy or radiotherapy potentially exposing the testes, † semen analysis is recommended as the gold standard primary surveillance modality for evaluation of spermatogenesis (expert opinion) Clinical measurement of testicular volume and of follicle-stimulating hormone and inhibin B might be reasonable for the identification of impaired spermatogenesis in survivors treated with potentially gonadotoxic chemotherapy or radiotherapy potentially exposing the testes* in whom semen analysis has been declined or is not possible and who desire assessment about possible future fertility. Be aware of the diagnostic limitations of these tests that may result in false positives or false negatives (level B evidence)
At what frequency and for how long should surveillance be performed?
Surveillance for impaired spermatogenesis should be performed only at the request of the survivor after informed discussion or when paternity is desired in the foreseeable future (expert opinion)
When should survivors with impaired spermatogenesis be referred?
Referral to a male reproductive health specialist should be offered to survivors with severely impaired spermatogenesis, defined as severe oligospermia (sperm counts ≤5 × 10⁶/mL), or to those who are seeking paternity after potentially gonadotoxic chemotherapy or radiotherapy potentially exposing the testes, and to those whose attempts to conceive have been unsuccessful for 6 months or more, regardless of sperm count, for detailed specialist counselling or consideration of sperm cryopreservation if not already performed (expert opinion)
Testosterone deficiency
Survivors treated with a potentially gonadotoxic agent, and their health-care providers, should be aware of the risk of testosterone deficiency and its implications for future health and fertility (supplemental literature search and expert opinion)
Counselling regarding the risk of testosterone deficiency and its implications for future health and fertility is recommended for survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more or with total body irradiation (supplemental literature search and expert opinion) Measurement of testosterone concentration in an early morning blood sample at clinically appropriate intervals is reasonable in postpubertal survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more or with TBI (expert opinion). In the presence of clinical signs of hypogonadism, or of previous low-normal or borderline testosterone concentrations, or if it is not possible to obtain an early morning blood sample, it is reasonable to measure luteinising hormone concentration in addition to testosterone (expert opinion) When should survivors with abnormalities of pubertal development be referred?
Referral to a paediatric endocrinologist is recommended for any survivor who has no signs of puberty by 14 years of age or failure of pubertal progression ¶ (expert opinion)
When should postpubertal survivors with suspected testosterone deficiency be referred??
Referral to a specialist in male reproductive health, andrology, endocrinology or urology (according to local referral pathways) is recommended for postpubertal survivors treated with radiotherapy potentially exposing the testes to 12 Gy or more or with TBI, and in whom laboratory results suggest testosterone deficiency (expert opinion)
Physical sexual dysfunction
Weak recommendation to do Survivors treated with one or more treatment modalities with potential to cause physical sexual dysfunction, or those who are hypogonadal, and their health-care providers, should be aware of the risk of physical sexual dysfunction (including erectile and ejaculatory dysfunction) and its implications for future health and fertility (supplemental literature search and expert opinion)
Counselling regarding the risk of physical sexual dysfunction (including erectile and ejaculatory dysfunction) and its implications for future health and fertility is recommended for survivors (supplemental literature search and expert opinion):
• Treated with surgery to the spinal cord, sympathetic nerves, or pelvis • Treated with radiotherapy potentially exposing testes or pelvis • Individuals who are hypogonadal Providers should take a relevant sexual history in survivors treated with surgery to the spinal cord, sympathetic nerves, or pelvis, or radiotherapy potentially exposing testes or pelvis, or those who are hypogonadal (expert opinion) When should survivors with suspected physical sexual dysfunction be referred?
Referral to a specialist in male reproductive health, andrology, endocrinology, or urology (according to local referral pathways) is recommended for survivors treated with surgery to the spinal cord, sympathetic nerves, or pelvis, or radiotherapy potentially exposing testes or pelvis, or those who are hypogonadal, and who have symptoms suggesting physical sexual dysfunction (expert opinion) 42 found that TBI was associated with a lower testosterone concentration compared with no TBI on univariable analysis, but not on multivariable analysis. However, the analyses in this study considered testosterone concentration as a continuous variable. Therefore, the fi ndings of the supplemental search were considered to have greater relevance to this clinical question, allowing a conclusion to be made that testicular radiotherapy doses of 12 Gy or more are probably associated with an increased risk of testosterone defi ciency.
The systematic search did not identify any studies that clarifi ed which survivors are at risk of physical sexual dysfunction, but the supplemental search found relevant evidence predominantly from studies of survivors of adult cancer or other patient populations, but refl ecting clinical experience in CAYA cancer survivors. A 2016 study 53 on erectile dysfunction in male childhood cancer survivors was published too late to be included in our systematic Review, although an abstract from the same group was included in our supplemental search. 54 Both publications described an increased risk of erectile dysfunction in survivors treated with higher dose (≥10 Gy) testicular radiotherapy, or surgery to the spinal cord or nerves, pelvis or prostate, when compared with their siblings. These sources of alternative evidence supported the conclusion that surgery to the spinal cord, sympathetic nerves or pelvis, radiotherapy potentially exposing the testes or pelvis, or any other treatment that causes hypogonadism, are each probably associated with an increased risk of physical sexual dysfunction.
A clear clinical and scientifi c consensus that semen analysis represents the gold standard for evaluating spermatogenesis exists. 55 However, some survivors might decline or be unable to provide semen for analysis, and single results can be misleading. 55 Health-care providers should be aware that results indicating severely impaired spermatogenesis can cause considerable distress to survivors, who might require appropriate psychological support. The eff ect of these results can be ameliorated by referral to a male reproductive health specialist to provide additional and more detailed counselling for the survivor, including information about future reproductive health options. This information can often provide some comfort for survivors.
Previously published long-term follow-up guidelines [18] [19] [20] have recommended measurement of testicular volume and serum FSH as surveillance. The DCOG guideline also recommended inhibin B measurement, particularly in the absence of semen analysis. A study 30 in adult survivors of childhood Hodgkin lymphoma reported that only inhibin B showed an independent correlation with sperm concentration. Our results confi rm that these measurements have fair diagnostic value for the detection of impaired spermatogenesis. Although testicular volume was not included as a clinical question, the studies identifi ed confi rmed that it has good diagnostic value (AUCs of ROC curves 0·7-0·9) in detecting oligozoospermia 38 or excluding azoospermia. 32, 37 Therefore, these measurements might be reasonable in survivors in whom semen analysis is not available and who desire assessment about future fertility potential. However, FSH and inhibin B have considerable limitations for surveillance because they can give false positive or false negative results. For example, one of the included studies 35 found that 22% of survivors with azoospermia had a normal (ie, false negative) FSH result, whereas 26% of those without azoospermia had an abnormal (ie, false positive) result. Analysis of the inhibin B to FSH ratio did not improve this situation. 35 Therefore, clinical treatment and personal factors also need to be considered in individual survivors when judging whether or not to use these tests for surveillance.
No evidence was identifi ed to inform recommendations regarding the frequency of surveillance for impaired spermatogenesis. This emphasises the importance of only undertaking such surveillance after informed discussion with survivors who desire paternity in the foreseeable future. The detection of severe oligozoospermia in individuals without previously stored sperm might suggest that referral to a male reproductive health specialist is appropriate for consideration of sperm cryopreservation to maximise the prospect of success with future attempts at assisted reproduction. 56 Consideration of sperm cryopreservation might be particularly important for survivors who are about to begin testosterone therapy, which could impair spermatogenesis further. 57 The rapid pace of advances in the fi eld of male reproductive health, for example the use of surgical testicular sperm extraction followed by intracytoplasmic sperm injection, 58 highlights the value of referral to a male reproductive health specialist even in azoospermic CAYA cancer survivors.
The recommendation for the surveillance modality for testosterone defi ciency in postpubertal survivors is focused primarily on serum testosterone measurement, whilst maximising fl exibility of clinical application by recommending measurement of LH in certain defi ned situations. The 2014 publication 59 of validated age-related normal values for total testosterone will facilitate early detection and appropriate referral of testosterone defi ciency, hence enabling reduction of morbidity.
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Figure 2: Harmonised recommendations for gonadotoxicity surveillance for male CAYA cancer survivors *Treatments with evidence and expert opinion for causing impaired spermatogenesis include cyclophosphamide, chlormethine, procarbazine (level C evidence), busulfan and cyclophosphamide or fl udarabine and melphalan for HSCT, ifosfamide, or radiotherapy potentially exposing the testes (supplemental literature search and expert opinion). †At least annually, with increasing frequency as clinically indicated depending on growth and pubertal progress. ‡Regular growth and pubertal monitoring should be started by no later than 12 years (and no earlier than 10 years) of age. §The pubertal increase in growth velocity may be impaired if growth hormone defi ciency is also present in survivors who received cranial radiation. ¶The absence of initiation of puberty (Tanner stage 2) in boys aged 14 years or older or failure to progress in pubertal stage for 6 months or more.
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Although testosterone defi ciency can be diagnosed readily by fi nding a low testosterone concentration in an early morning blood sample, the importance of borderline values might be uncertain. In such cases, serum LH concentration facilitates clinical evaluation. Surveillance might facilitate earlier detection of testosterone defi ciency, which is important as the condition itself might lead to depression, 12 and could reduce the probability of seeking medical consultation with (or even within) planned follow-up and surveillance. If testosterone defi ciency is suspected, referral for specialist assessment is indicated because, although testosterone replacement treatment may be appropriate in defi cient patients following accepted endocrine guidelines, the potential benefi ts and risks of treatment need to be considered appropriately for each individual. 40, [61] [62] [63] [64] [65] Defi nitions of failure of pubertal progression are not standardised, but our pragmatic recommendation to seek specialist referral following no advancement in Tanner stage over a 6-month period is intended to avoid delayed referral in a population of survivors at high risk of pubertal failure and consequent potential impairment of growth, metabolic health, bone mineral accretion, and quality of life as a result of testosterone defi ciency. 64 Several factors can infl uence the decision to undertake surveillance investigations and subsequently to refer survivors for specialist opinion, including perceptions of the reliability and utility of surveillance investigations, complexities in their interpretation, eff ects of the condition itself, treatments that could potentially be available to manage the condition, and possible treatment toxicities.
The task of harmonising male gonadal dysfunction surveillance guidelines was strengthened by our evidence-based approach with standardised outcome defi nitions, transparent presentation of the quality of available evidence and the strength of recommendation, and the multidisciplinary approach necessary to achieve consensus. When evidence was scarce for CAYA cancer survivors, we carefully extrapolated information from other populations.
The process used in the development of this guideline has revealed several substantial knowledge gaps for clinical research that could improve surveillance of gonadotoxicity in male CAYA cancer survivors. Research to address these gaps should be approached in a systematic, comprehensive manner by suffi ciently large single-institution studies, or national and international multicentre collaborative projects.
This male gonadotoxicity surveillance guideline, and the international harmonisation initiative that underpins it, aims to improve health outcomes by facilitating more consistent long-term follow-up care for current male CAYA cancer survivors and promote strategically planned ongoing research that will inform future guidelines updates.
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